German multinational corporation Hartmann, a CataloniaBio  & HealthTech member, will invest €10 million between 2019 and 2021 in its two plants in Mataró and Montornès del Vallès (Barcelona), according to financial newspaper Expansión.

The Mataró factory is a global benchmark in developing and manufacturing adhesive healthcare products and is currently responsible for production of the company’s popular plasters.

In 2017, Hartmann acquired the Lindor brand from Procter & Gamble and saw revenue of €175 million in Spain, up 52% from 2016. The company is open to new acquisitions to continue growing in Spain and expects to see sales of €250 ...


Banc Sabadell ha obert la nova convocatòria BStartup Health per donar suport a projectes que es trobin en fases inicials de l'àmbit de la salut (dispositius mèdics, salut digital, diagnòstic i terapèutic). Els tres projectes seleccionats rebran 75.000 euros d’inversió i un pla d’acompanyament.

El comitè cientificotècnic està format per Carlos Gallardo, CEO de CG Health Partners i membre del consell d’Almirall; Damià Tormo, soci de Columbus Venture Partners, i Montserrat Vendrell, sòcia d’Alta Life Sciences i membre de la junta de CataloniaBio & HealthTech. A més d'aquest comitè, els projectes se seleccionaran amb el suport de ...


Bio€quity Europe, the longest investor event for the European biotechnology sector, will take place in Barcelona for the first time on 20th and 21st May 2019. The conference will be held in Barcelona at the initiative of the Host Regional Committee, which brings together Biocat, Ysios Capital, ACCIÓ and CataloniaBio & HealthTech

Bio€quity Europe —organised by BioCentury and EBD Group— has showcased more than 800 leading European companies and thousands of investment and pharma business development professionals. More than 550 delegates from 26 nations attended latest edition in Ghent.

"Barcelona has all of the key ingredients for a ...


FreeOx Biotech, spin-out of Hospital Clinic Barcelona-IDIBAPS and member of CataloniaBio & HealthTech, has opened a round of investment hoping to raise €500,000. The company’s goal this year is to accelerate development and the regulatory process for its drug candidate Ox-01, which has completed phase IIb, and begin preclinical trials with Ox-02. Both drugs are being used to treat stroke and other diseases of the central nervous system (CNS).

“We’re looking for a total of €500,000 and we’ve already raised €200,000 from two private investors,” explained Carlos Lurigados, co-founder and CEO of FreeOx. These investors ...


The Genesis Ventures investment fund, managed by Genesis Biomed consultancy, has made its first investment of €75,000 in the NeuroHeal research project at the Institut de Neurociències (INc) at the Autonomous  University of Barcelona (UAB), led by Dr Caty  Casas. The agreement will allow them to accelerate development of the product and move towards creating a new spin-off.

NeuroHeal is a new first line of treatment to accelerate neuroregeneration  and reduce muscle atrophy.

Genesis Ventures, which was first presented  at the Barcelona Science Park in November 2017, is committed to projects in the very early stages to help them ...